In March 2025, the company announced new strategies for just a direct-to-buyer presenting of its Wegovy weight loss drug. The company set up a different pharmacy, referred to as NovoCare, which might cost buyers $499 every month for usage of the drug, fewer than 50 percent the expense of the drug as a result of other pharmaceutical distribution net